| PubMed |
Abstract |
RScore(About this table) |
| 11739199 |
Gajate C, Mollinedo F: The antitumor ether lipid ET-18-OCH (3) induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood. 2001 Dec 15;98(13):3860-3.
|
2(0,0,0,2) |
Details |
| 12369895 |
Gajate C, Mollinedo F: Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH (3) (edelfosine), a proapoptotic agent in tumor cells. Curr Drug Metab. 2002 Oct;3(5):491-525.
Recent progress has allowed unraveling the molecular mechanism underlying the apoptotic action of ET-18-OCH (3), leading to the notion that ET-18-OCH (3) is selectively incorporated into tumor cells and induces cell death by intracellular activation of the cell death receptor Fas/CD95. |
2(0,0,0,2) |
Details |
| 10552970 |
Cuvillier O, Mayhew E, Janoff AS, Spiegel S: Liposomal ET-18-OCH (3) induces cytochrome c-mediated apoptosis independently of CD95 (APO-1/Fas) signaling. Blood. 1999 Nov 15;94(10):3583-92.
|
1(0,0,0,1) |
Details |
| 15289504 |
Gajate C, Del Canto-Janez E, Acuna AU, Amat-Guerri F, Geijo E, Santos-Beneit AM, Veldman RJ, Mollinedo F: Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis. J Exp Med. 2004 Aug 2;200(3):353-65.
We have discovered a new and specific cell-killing mechanism mediated by the selective uptake of the antitumor drug 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-18-OCH (3), Edelfosine) into lipid rafts of tumor cells, followed by its coaggregation with Fas death receptor (also known as APO-1 or CD95) and recruitment of apoptotic molecules into Fas-enriched rafts. |
1(0,0,0,1) |
Details |